Salute

Debiopharm International SA Has Won Its Patent Infringement Suit for Elplat® Against Nippon Kayaku Co., Ltd.

- LAUSANNE, Switzerland, March 4, 2016 /PRNewswire/ --

Debiopharm International SA (Debiopharm), part of Debiopharm Group™, a Swiss-based global biopharmaceutical company today announces that the Tokyo District Court granted Debiopharm an overall victory for the first instance demanding the suspension of patent infringement of the formulation patent owned by Debiopharm (Patent N- 4430229) related to Elplat® (Oxaliplatin) Drip Infusion of 50, 100 and 200 mg a treatment drug for cancer.

The Court ruled that the sale of the generic version of the cancer drug by Nippon Kayaku Co., Ltd. (Nippon Kayaku) infringed Debiopharm's Japanese patent.

Debiopharm filed a patent infringement law suit with the Tokyo District Court on May 8th, 2015 against Nippon Kayaku, the distributor of the generic version of Elplat® treatment. In accordance with this judgement, a provisional disposition order was issued for the company to suspend the distribution of products. Twelve other pending infringement actions were also filed by Debiopharm against all the generics companies that started to commercialize their generic version of Elplat® in 2015.

About Elplat® Elplat® is an anticancer platinum drug, for which Yakult Honsha, Co., Ltd. acquired development and commercialization rights in Japan from its licensor Debiopharm International SA (Switzerland) in 1997. Elplat® was approved for the indication for the treatment of "curatively unresectable advanced/recurrent colorectal cancer" in March 2005, and launched on the market in April of the same year. In August 2009, Elplat® became indicated for "postoperative adjuvant chemotherapy for colon cancer". An additional dosage and administration for "curatively unresectable advanced/recurrent colorectal cancer" was approved in September 2009, and an additional dosage and administration for "postoperative adjuvant chemotherapy for colon cancer" was approved in November 2011. Subsequently, Elplat® was approved for the indication for the treatment of "curatively unresectable pancreatic carcinoma" in December 2013. And furthermore, Elplat® was approved for the indication for "unresectable advanced or recurrent gastric cancer" in March 2015 and then "gastric cancer" in November 2015, integrating "unresectable advanced or recurrent gastric cancer" and "postoperative adjuvant chemotherapy for gastric cancer".

About Debiopharm International SA Debiopharm Group™ is a Swiss-based global biopharmaceutical group of four companies active in drug development, GMP manufacturing of proprietary drugs, diagnostics, and investment management. Debiopharm International SA is focused on the development of prescription drugs that target unmet medical needs. The company in-licenses and develops promising drug candidates. The products are commercialized by pharmaceutical out-licensing partners to give access to the largest number of patients worldwide.

For more information, please visit http://www.debiopharm.com

We are on Twitter. Follow us @DebiopharmNews at http://twitter.com/DebiopharmNews

Debiopharm International SA ContactChristelle Tur Communication Coordinatorchristelle.tur@debiopharm.comTel: +41(0)21-321-01-11

Additional Media ContactsIn London Maitland Chiara Valsangiacomocvalsangiacomo@maitland.co.uk Tel: +44(0)20-7379-5151

Russo Partners, LLCLena Evans Assistant Vice Presidentlena.evans@russopartnersllc.comTel: +1-212-845-4262

4 marzo 2016 ADNKronos
Tag scienza - salute -

Codici Sconto

67 Coupon e Nuovi Sconti
Codice Sconto Asos

Codice Sconto Asos

Coupon Asos 50 euro

Codice Sconto Farfetch

Codice Sconto Farfetch

Codice Sconto Farfetch 15%

Codice Sconto Luisa Via Roma

Codice Sconto Luisa Via Roma

Codice Sconto Luisa Via Roma -15% extra

Codice Sconto Yoox

Codice Sconto Yoox

Codice Sconto Yoox newsletter di 30€

Codice Sconto Zalando Prive

Codice Sconto Zalando Prive

Zalando Prive Coupon Spedizione a soli 4,90€

Codice Sconto Footlocker

Codice Sconto Footlocker

Codice Sconto FootLocker 10€

Ora in Edicola
Scopri il mondo Focus. Ogni mese in edicola potrai scegliere la rivista che più di appassiona. Focus il magazine di divulgazione scientifica più letto in Italia, Focus Storia per conoscere la storia in modo nuovo ed avvincente e Focus Domande & Risposte per chi ama l'intrattenimento curioso e intelligente.

Sulle orme di Marco Polo, il nostro viaggiatore più illustre che 700 anni fa dedicò un terzo della sua vita all’esplorazione e alla conoscenza dell’Oriente, in un’esperienza straordinaria che poi condivise con tutto il mondo attraverso "Il Milione". E ancora: un film da Oscar ci fa riscoprire la figura di Rudolf Höss, il comandante di Auschwitz che viveva tranquillo e felice con la sua famiglia proprio accanto al muro del Lager; le legge e le norme che nei secoli hanno vessato le donne; 100 anni fa nasceva Franco Basaglia, lo psichiatra che "liberò" i malati rinchiusi nei manicomi.

ABBONATI A 29,90€

Che cosa c’era "prima"? Il Big Bang è stato sempre considerato l’inizio dell’universo, ma ora si ritiene che il "nulla" precedente fosse un vuoto in veloce espansione. Inoltre, come si evacua un aereo in caso di emergenza? Il training necessario e gli accorgimenti tecnici; che effetto fa alla psiche il cambiamento climatico? Genera ansia ai giovani; esiste la distinzione tra sesso e genere tra gli animali? In alcune specie sì. Con quali tecniche un edificio può resistere a scosse devastanti? Siamo andati nei laboratori a prova di terremoti.

 

ABBONATI A 31,90€
Follow us